Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with<i>Clostridium Difficile</i>(RAPID): a randomised placebo controlled trial

Giles Major(University Hospital of Lausanne), Robert E. Spiller(Nottingham University Hospitals NHS Trust), Mathew Diggle(Nottingham University Hospitals NHS Trust), Kirsty Sprange(University of Nottingham), Lucy Bradshaw(University of Nottingham), Nafisa Boota(University of Leicester), Aida Jawhari(Nottingham University Hospitals NHS Trust), Alan Montgomery(University of Nottingham)

Gut

September 25, 2018

10.1136/gutjnl-2018-316794

Cited by 34

Related Papers

Functional Bowel Disorders

|Gastroenterology|2006|4.8k

Bowel Disorders

|Gastroenterology|2016|2.8k

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute <i>Campylobacter</i> enteritis and in post-dysenteric irritable bowel syndrome

|Gut|2000|1.2k

Postinfectious Irritable Bowel Syndrome

|Gastroenterology|2009|1k

Irritable bowel syndrome

|Nature Reviews Disease Primers|2016|981